Johnson & Johnson (JNJ), together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices & Diagnostics. This dividend king has paid dividends since 1944 and has managed to increase them for 52 years in a row.
The company’s latest dividend increase was announced in April 2014 when the Board of Directors approved a 6.10% increase in the quarterly dividend to 70 cents /share. The company’s peer group includes Novartis (NVS), Pfizer (PFE) and Covidien (COV).
Over the past decade this dividend growth stock has delivered an annualized total return of 12.10% to its shareholders.
Currently, the stock is attractively valued at 17.80 times forward earnings and a current yield of 2.70%. I last purchased shares of the stock in 2013, and the only reason I am hesitating to add more is because the company is one of the five highest weighted in my portfolio.
Check the full analysis at Seeking Alpha
Full Disclosure: Long JNJ
Relevant Articles:
- Multi-Generational Dividend investing
- Dividend Investors Will Make Money Even if the Stock Market Closed for Ten Years
- Can everyone achieve financial independence with Dividend Paying Stocks?
- Dividend Growth Stocks are Compounding Machines
- Two Dividend Kings Extending Their Dividend Growth Streaks
This article was written by Dividend Growth Investor. If you enjoyed this article, please subscribe to have future articles emailed to you [Email] or follow me on Twitter [Twitter]
2 days ago
